immunity News and Research

RSS

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory.

8 Feb 2022

UTSA awarded $6.8 million grant to establish a Coccidioidomycosis Collaborative Research Center

Mycology and immunology researchers from The University of Texas at San Antonio have been selected to receive a five-year, $6.8 million grant from the National Institutes of Health to establish a San Antonio-based Coccidioidomycosis Collaborative Research Center (SA-CCRC) focused on developing therapeutics and vaccines against coccidioidomycosis.

8 Feb 2022

Study shows how gut bacteria could undermine immunity in pancreatic cancer

Researchers at the University of Toronto and University Health Network have shown how probiotic bacteria in the gut could undermine immunity in pancreatic cancer, pointing toward more personalized cancer treatments.

8 Feb 2022

The B and T cell responses to SARS-CoV-2

Researchers assess the correlation between humoral and cell-mediated responses to SARS-CoV-2 in symptomatic and asymptomatic individuals.

8 Feb 2022

PCR data sheds light on the dynamics of interspecies pathogen-pathogen interactions

The new study uses PCR data on 17 different pathogens, collected from clinical samples as part of the Seattle Flu Study, a community-based surveillance study of respiratory viral infections.

8 Feb 2022

Reanalysis of the efficacy of COVID-19 vaccines

In a new study, researchers investigated the impact of trial study design and other parameters on the estimates of COVID-19 vaccine efficacy.

8 Feb 2022

Efficacy of MVA-CoV2-S vaccination to prevent SARS-CoV-2 cerebral infection and associated damage

Researchers demonstrated that an MVA vector expressing the SARS-CoV-2 spike protein was 100% effective in preventing neuroinvasion and brain damage by SARS-CoV-2 in transgenic mice.

8 Feb 2022

Characterization of the severity of Omicron relative to Delta in England

Researchers assessed the relative risks of hospitalization and death by SARS-CoV-2 Omicron variant compared to those by Delta (B.1.617.2).

8 Feb 2022

SARS-CoV-2 infection-induced antibodies may last more than 20 months

A recent research letter published in the JAMA demonstrated the prevalence and the longevity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) unvaccinated United States (US) adults recovered from the disease in the long term.

7 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

7 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients

A new study analyzes neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 D614G, as well as some variants of concern.

7 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

USP22 crucial for type III interferon signaling and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, a team of researchers demonstrated that ubiquitin-specific peptidase 22 (USP22) is a crucial regulator of basal interferon (IFN) signaling in native human intestinal epithelial cells (hIECs).

7 Feb 2022

Booster vaccines found to augment T-cell responses to SARS-CoV-2 Omicron

In a recent study published in the latest issue of the journal Cell, a team of researchers evaluated T-cell reactivity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant's spike (S) and non-spike proteins.

6 Feb 2022

Vaccine-induced immunity and prior infection effective in reducing COVID severity in reinfections

A recent study posted to the Research Square* preprint server and under consideration for inclusion in the journal Scientific Reports assessed the epidemiology of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) reinfections.

6 Feb 2022

Researchers discover a new function of anti-HIV-1 antibodies

Teams at the Institut Pasteur, CNRS, Vaccine Research Institute (VRI) and Université de Paris have discovered a new function of anti-HIV-1 antibodies by applying cutting-edge microscopy techniques to in vitro viral cultures.

6 Feb 2022

Booster dose of Pfizer-BioNTech COVID vaccine protects elderly against Omicron

Researchers discuss the impact of mRNA booster immunization on the neutralizing activity against the SARS-CoV-2 Omicron variant in the elderly.

6 Feb 2022

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Researchers investigate the relationship between TSD and COVID-19.

6 Feb 2022

immunity News and Research

Old FDA-approved drug may protect against lung injury and blood clots in severe COVID-19

UTSA awarded $6.8 million grant to establish a Coccidioidomycosis Collaborative Research Center

Study shows how gut bacteria could undermine immunity in pancreatic cancer

The B and T cell responses to SARS-CoV-2

PCR data sheds light on the dynamics of interspecies pathogen-pathogen interactions

Reanalysis of the efficacy of COVID-19 vaccines

Efficacy of MVA-CoV2-S vaccination to prevent SARS-CoV-2 cerebral infection and associated damage

Characterization of the severity of Omicron relative to Delta in England

SARS-CoV-2 infection-induced antibodies may last more than 20 months

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

Colchicine holds promise to reduce the risk of severe COVID-19

Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

USP22 crucial for type III interferon signaling and SARS-CoV-2 infection

Booster vaccines found to augment T-cell responses to SARS-CoV-2 Omicron

Vaccine-induced immunity and prior infection effective in reducing COVID severity in reinfections

Researchers discover a new function of anti-HIV-1 antibodies

Booster dose of Pfizer-BioNTech COVID vaccine protects elderly against Omicron

Women, smokers and drinkers more likely to develop taste or smell disorders from COVID

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News